在心力衰竭中,BET基因调解转录暂停释放
Priti Anand1, Jonathan D Brown, Charles Y Lin
1Case Cardiovascular Research Institute, Department of Medicine, Case Western Reserve University School of Medicine, and Harrington Heart & Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Cell
|August 6, 2013
概括
基因抑制剂BET通过调节基因表达来抑制心力衰竭的进展. 这项研究确定了BET蛋白作为治疗心力衰竭和心脏重塑的关键治疗点.
科学领域:
- 分子生物学分子生物学
- 心血管研究的心血管研究.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 心力衰竭 (HF) 涉及复杂的基因调节和染色质变化.
- 希斯乙转移酶和染色质过乙化与HF病理基因激活有关.
研究的目的:
- 调查乙-氨酸读取蛋白的作用,特别是腺素,在心力衰竭的发病.
- 为了确定BET基蛋白蛋白是否对高频率的基因控制至关重要.
主要方法:
- 利用化学遗传方法研究HF中的BETodomain蛋白.
- 进行了整合性转录和表观基因组分析.
- 评估了BET抑制对心肌细胞缩 in vitro和心脏重塑 in vivo的影响.
主要成果:
- 确立了BET原蛋白在HF基因调节中的中心作用.
- 证明BET抑制有效抑制心肌细胞缩和病态心脏重塑.
- 揭示了BET蛋白作为HF相关基因的关键暂停释放因子.
结论:
- 表观遗传读者,特别是BET蛋白,对于转录性暂停释放在HF病变发生过程中至关重要.
- 在心力衰竭治疗中,BET协激活蛋白代表了有前途的治疗点.
相关概念视频
Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626


